225 related articles for article (PubMed ID: 31310602)
1. Morphophenotypic classification of tumor organoids as an indicator of drug exposure and penetration potential.
Karolak A; Poonja S; Rejniak KA
PLoS Comput Biol; 2019 Jul; 15(7):e1007214. PubMed ID: 31310602
[TBL] [Abstract][Full Text] [Related]
2. [Spheroids to organoids: Solid cancer models for anticancer drug discovery].
Alzeeb G; Corcos L; Le Jossic-Corcos C
Bull Cancer; 2022 Jan; 109(1):49-57. PubMed ID: 34848046
[TBL] [Abstract][Full Text] [Related]
3. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
Dzobo K
OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.
Praharaj PP; Bhutia SK; Nagrath S; Bitting RL; Deep G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):117-127. PubMed ID: 29360544
[TBL] [Abstract][Full Text] [Related]
5. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
[TBL] [Abstract][Full Text] [Related]
6. Liver-Tumor Hybrid Organoids for Modeling Tumor Growth and Drug Response In Vitro.
Skardal A; Devarasetty M; Rodman C; Atala A; Soker S
Ann Biomed Eng; 2015 Oct; 43(10):2361-73. PubMed ID: 25777294
[TBL] [Abstract][Full Text] [Related]
7. Establishment and Long-Term Expansion of Small Cell Lung Cancer Patient-Derived Tumor Organoids.
Choi SY; Cho YH; Kim DS; Ji W; Choi CM; Lee JC; Rho JK; Jeong GS
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572899
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Cell and Organoid-Level Analysis of Patient-Derived 3D Organoids to Evaluate Tumor Cell Growth Dynamics and Drug Response.
Kim S; Choung S; Sun RX; Ung N; Hashemi N; Fong EJ; Lau R; Spiller E; Gasho J; Foo J; Mumenthaler SM
SLAS Discov; 2020 Aug; 25(7):744-754. PubMed ID: 32349587
[TBL] [Abstract][Full Text] [Related]
9. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.
Votanopoulos KI; Mazzocchi A; Sivakumar H; Forsythe S; Aleman J; Levine EA; Skardal A
Ann Surg Oncol; 2019 Jan; 26(1):139-147. PubMed ID: 30414038
[TBL] [Abstract][Full Text] [Related]
10. A novel integrated system using patient-derived glioma cerebral organoids and xenografts for disease modeling and drug screening.
Zhang L; Liu F; Weygant N; Zhang J; Hu P; Qin Z; Yang J; Cheng Q; Fan F; Zeng Y; Tang Y; Li Y; Tang A; He F; Peng J; Liao W; Hu Z; Li M; Liu Z
Cancer Lett; 2021 Mar; 500():87-97. PubMed ID: 33309780
[TBL] [Abstract][Full Text] [Related]
11. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
12. Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation.
Pasch CA; Favreau PF; Yueh AE; Babiarz CP; Gillette AA; Sharick JT; Karim MR; Nickel KP; DeZeeuw AK; Sprackling CM; Emmerich PB; DeStefanis RA; Pitera RT; Payne SN; Korkos DP; Clipson L; Walsh CM; Miller D; Carchman EH; Burkard ME; Lemmon KK; Matkowskyj KA; Newton MA; Ong IM; Bassetti MF; Kimple RJ; Skala MC; Deming DA
Clin Cancer Res; 2019 Sep; 25(17):5376-5387. PubMed ID: 31175091
[TBL] [Abstract][Full Text] [Related]
13. Tumor organoids: Opportunities and challenges to guide precision medicine.
Veninga V; Voest EE
Cancer Cell; 2021 Sep; 39(9):1190-1201. PubMed ID: 34416168
[TBL] [Abstract][Full Text] [Related]
14. Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance.
Liu J; Li P; Wang L; Li M; Ge Z; Noordam L; Lieshout R; Verstegen MMA; Ma B; Su J; Yang Q; Zhang R; Zhou G; Carrascosa LC; Sprengers D; IJzermans JNM; Smits R; Kwekkeboom J; van der Laan LJW; Peppelenbosch MP; Pan Q; Cao W
Cell Mol Gastroenterol Hepatol; 2021; 11(2):407-431. PubMed ID: 32932015
[TBL] [Abstract][Full Text] [Related]
15. Applications of patient-derived tumor xenograft models and tumor organoids.
Yoshida GJ
J Hematol Oncol; 2020 Jan; 13(1):4. PubMed ID: 31910904
[TBL] [Abstract][Full Text] [Related]
16. A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids.
Phan N; Hong JJ; Tofig B; Mapua M; Elashoff D; Moatamed NA; Huang J; Memarzadeh S; Damoiseaux R; Soragni A
Commun Biol; 2019; 2():78. PubMed ID: 30820473
[TBL] [Abstract][Full Text] [Related]
17. Patient-Derived Organoids for Precision Cancer Immunotherapy.
Grönholm M; Feodoroff M; Antignani G; Martins B; Hamdan F; Cerullo V
Cancer Res; 2021 Jun; 81(12):3149-3155. PubMed ID: 33687948
[TBL] [Abstract][Full Text] [Related]
18. Organoids: An intermediate modeling platform in precision oncology.
Jin MZ; Han RR; Qiu GZ; Ju XC; Lou G; Jin WL
Cancer Lett; 2018 Feb; 414():174-180. PubMed ID: 29174804
[TBL] [Abstract][Full Text] [Related]
19. Reconstructing the tumor architecture into organoids.
Luo Z; Zhou X; Mandal K; He N; Wennerberg W; Qu M; Jiang X; Sun W; Khademhosseini A
Adv Drug Deliv Rev; 2021 Sep; 176():113839. PubMed ID: 34153370
[TBL] [Abstract][Full Text] [Related]
20. 3D modeling in cancer studies.
Atat OE; Farzaneh Z; Pourhamzeh M; Taki F; Abi-Habib R; Vosough M; El-Sibai M
Hum Cell; 2022 Jan; 35(1):23-36. PubMed ID: 34761350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
